Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide in Myelodysplastic Syndromes
NCT00020969Phase 2Terminated
- Sponsor
- CTI BioPharma Corp.
- Start
- Mar 2001
- Primary completion
- Jan 2005
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of arsenic trioxide in myelodysplastic syndrome (MDS), sponsored by CTI BioPharma Corp.. Started Mar 2001; status: terminated.
02
Drugs
arsenic trioxide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00020969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00020969.